New Delhi: Hyderabad-based Bharat Biotech on Wednesday claimed that its Covid-19 vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
In a statement, Bharat Biotech said, "Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants of Covid-19."
It also mentioned that earlier studies demonstrated the neutralising potential of Covaxin against SARS-CoV-2 Variants of Concern —Alpha, Beta, Delta, Zeta and Kappa.
The study will be published on the pre-print server, medRXiv, shortly.
Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralising Omicron and Delta variants on a live virus neutralization assay. Hyderabad-based Bharat Biotech claimed that the neutralisation activity of Covaxin boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant and found more than 90 per cent of all individuals boosted with Covaxin showed neutralising antibodies. All participants received an initial two-dose schedule of Covaxin on Day 0 and Day 28.
"As the dominant Covid-19 variant throughout the world, Omicron poses a serious public health concern," said Mehul Suthar, PhD Assistant Professor, Emory Vaccine Centre who led the laboratory analysis.
Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations, said the statement.
"We are in a continuous state of innovation and product development for Covaxin. The positive neutralisation responses against the Omicron and Delta variants validate our hypothesis of a multi-epitope vaccine generating both humoral and cell-mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covaxin as a universal vaccine for adults and children," said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.
"The global impact of Omicron shows us that the fight against coronavirus continues, and we are encouraged that these data demonstrate the value of Covaxin as a primary and booster vaccine. These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations," said Dr Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc.